8-K: Jaguar Health's Phase 3 Cancer Drug Trial Fails Primary Endpoint, Shows Promise in Subgroups

Jaguar Health's Phase 3 OnTarget trial for crofelemer did not meet its primary endpoint across all tumor types, but showed clinically relevant signals in breast and respiratory cancer subgroups.

Summary

• Jaguar Health announced the results of its Phase 3 OnTarget trial for crofelemer, a drug intended to prevent diarrhea in cancer patients undergoing targeted therapy.
• The trial, which included patients with 10 different tumor types, did not meet its primary endpoint of reducing the average number of weekly loose stools across all tumor types.
• However, subgroup analysis revealed clinically meaningful improvements in patients with breast and respiratory cancers, including lung cancer, who comprised over 75% of the trial participants.
• The study included 287 patients from 49 sites across multiple countries and involved 24 different targeted agents, with or without standard chemotherapy.
• The trial consisted of a 12-week double-blind treatment phase followed by a 12-week double-blind extension phase, with only the initial 12-week data analyzed so far.
• The company plans to further analyze the data, including the 12-week extension phase, and engage with the FDA to determine the most efficient pathway for bringing crofelemer to market for these specific patient subgroups.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive signals in subgroups, the failure to meet the primary endpoint is a significant setback. The company's plans for future analysis and FDA engagement provide some hope, but the overall tone is cautious.

Positives

• Crofelemer showed clinically meaningful improvement in prespecified subgroups of breast and respiratory cancer patients.
• The drug was well tolerated, with an adverse event profile similar to placebo.
• The company is planning to engage with the FDA to seek the most efficient pathway to bring crofelemer to market for the identified subgroups.
• The company is expanding its commercial footprint beyond HIV-related supportive care with the planned launch of Gelclair in Q4 2024.
• The study included patient reported outcomes which are important to patients.

Negatives

• The OnTarget trial did not meet its primary endpoint for all tumor types.
• The initial analysis only covers the first 12 weeks of the study, with the 12-week extension data yet to be analyzed.

Risks

• The failure to meet the primary endpoint across all tumor types may impact the overall market potential of crofelemer.
• Further analysis of the full data, including the extension phase, is needed to confirm the benefits observed in the subgroups.
• Regulatory approval for the specific subgroups is not guaranteed and will depend on discussions with the FDA.
• The company faces competition in the cancer supportive care market.

Future Outlook

The company expects to complete the analysis of full data for the first and second 12-week periods and disclose the results in future presentations and publications. They also plan to engage with the FDA to seek the most efficient pathway to bring crofelemer to cancer patients and address the side effect of CTD. The company also expects to launch Gelclair in the U.S. in Q4 2024 and expects proof-of-concept data from multiple clinical investigations of crofelemer for short bowel syndrome and microvillus inclusion disease by the end of 2024 and throughout 2025.

Management Comments

• Lisa Conte, Founder, President, and Chief Executive Officer of Jaguar, stated that the trial did not meet the primary endpoint given the heterogenous nature of the patients enrolled.
• Lisa Conte also stated that they are pleased with the preliminary analysis showing a clinically meaningful benefit in response to crofelemer in patients with breast and respiratory cancers.
• Pablo Okhuysen, MD, Principal Investigator of the OnTarget clinical trial, mentioned that they will continue to evaluate important OnTarget findings, with further analyses.

Industry Context

The announcement highlights the challenges in developing treatments for cancer therapy-related diarrhea, a significant unmet medical need. The focus on specific subgroups, such as breast and respiratory cancer patients, reflects a trend towards personalized medicine and targeted therapies. The company's efforts to expand beyond HIV-related supportive care align with the broader industry trend of diversifying product portfolios.

Comparison to Industry Standards

• The OnTarget trial's design, including 10 different tumor types and 24 targeted agents, is unusually broad compared to many clinical trials that focus on specific cancer types or therapies.
• The use of patient-reported outcomes as a primary endpoint is a positive step towards patient-centric drug development, aligning with industry trends.
• The results, while not meeting the primary endpoint across all tumor types, are similar to other trials where subgroup analysis reveals efficacy in specific patient populations.
• The company's focus on botanical drugs aligns with a growing interest in natural and plant-based therapies, but also presents unique regulatory and manufacturing challenges.

Stakeholder Impact

• Shareholders may react negatively to the failure to meet the primary endpoint, but positively to the subgroup analysis.
• Patients with breast and respiratory cancers may benefit from the potential availability of crofelemer.
• Employees may be impacted by the company's strategic decisions based on the trial results.
• The company's suppliers and partners may be affected by the future development and commercialization plans.

Next Steps

• The company will complete the analysis of full data for the first and second 12-week periods.
• The company will disclose the results in future presentations and publications.
• The company will engage in discussions with the FDA to seek the most efficient pathway to bring crofelemer to cancer patients.
• The company will launch Gelclair in the U.S. in Q4 2024.
• The company will continue clinical investigations of crofelemer for short bowel syndrome and microvillus inclusion disease with proof-of-concept data targeted for end of 2024 and throughout 2025.

Key Dates

Keywords

crofelemer, cancer therapy-related diarrhea, OnTarget trial, breast cancer, lung cancer, targeted therapy, FDA, clinical trial, gastrointestinal, supportive care